Form 4: ImmunityBio CEO Adcock's Year-End Stock Transactions

ImmunityBio CEO Richard Adcock reported the vesting of restricted stock units and subsequent tax-related share disposals on December 31, 2025.

Summary

• Richard Adcock, CEO and President of ImmunityBio, Inc., reported transactions involving the company's common stock and Restricted Stock Units (RSUs) on December 31, 2025.
• 34,483 shares of common stock were acquired by Adcock upon the vesting of RSUs.
• 17,510 shares of common stock were disposed of at a price of $1.98 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Adcock directly beneficially owns 351,391 shares of common stock.
• Adcock also directly beneficially owns 51,731 Restricted Stock Units (RSUs).
• The RSU vesting on December 31, 2025, represented 20% of the original 172,420 RSUs granted.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled executive compensation event (RSU vesting and tax-related share disposal) that does not provide new material information regarding the company's operational performance, financial health, or strategic direction. Therefore, the sentiment is neutral.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates continued executive compensation and alignment of management's interests with shareholder value.

Negatives

• No direct negatives identified; the disposal of shares was for tax withholding purposes, which is a routine event associated with RSU vesting.

Risks

• The Power of Attorney explicitly states that neither ImmunityBio, Inc. nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with Sections 13 or 16 of the Exchange Act or Rule 144, or for any disgorgement of profits under Section 16(b) of the Exchange Act.
• The undersigned remains solely responsible for compliance with their obligations under Section 13 or Section 16 of the Exchange Act, including reporting requirements.

Future Outlook

The remaining Restricted Stock Units (RSUs) held by Richard Adcock are scheduled to vest on December 31, 2026.

Industry Context

This filing details a routine executive compensation event (RSU vesting and tax-related share disposal) for a biotechnology company, which is a common practice across various industries for aligning executive incentives with company performance and is not indicative of broader industry trends.

Stakeholder Impact

• Shareholders: The transactions represent a routine part of executive compensation, with minimal direct impact on the company's overall share structure or market valuation. The disposal of shares for tax purposes is a common occurrence and not a discretionary sale.
• Employees: The vesting of RSUs reflects standard executive compensation practices, which can be a component of overall employee incentive structures.

Next Steps

• The remaining Restricted Stock Units (RSUs) held by Richard Adcock are scheduled to vest on December 31, 2026.

Key Dates

Recommendation

This Form 4 details a routine, pre-scheduled vesting of Restricted Stock Units and a subsequent tax-related sale by a key executive. Such transactions are part of standard executive compensation and do not provide new material information regarding the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation.

Keywords

ImmunityBio, IBRX, Richard Adcock, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Disposal, Tax Withholding